| 摘要: |
| 目的探讨X射线损伤交叉互补蛋白1（XRCC1)基因多态性与弥漫大B细胞型非霍奇金淋巴瘤（DLBCL）患者预后的关系。方法选取XRCC1基因3个单核苷酸多态性（SNPs）对DLBCL患者进行基因分型，并回顾分析患者预后情况，采用logistic回归分析XRCC1基因型与患者预后的关系。结果入选65例患者，平均年龄（59.7±8.0岁）；其中肿瘤相关死亡患者31例（47.7%）。XRCC1基因rs25487基因型频率在死亡组与存活组无统计学差异（P＞0.05），而等位基因频率两组间有统计学差异，其中A等位基因频率在死亡组中明显高于存活组（40.3%vs22.1%，P＜0.05）。AA、GA、GG3组基因型患者肿瘤相关病死率分别为75.0%（6/8）、54.2%（13/24）、36.4%（12/33）。rs25487位点A等位基因的加性模型中，每增加一个拷贝的A等位基因，风险是增加前的2.208倍（95%CI：1.039~4.694，P＜0.05）。校正年龄、性别、吸烟、B症状及和治疗方式后，A等位基因仍然显著增高患者死亡风险（OR=2.382，95%CI：1.057~5.367，P＜0.05）。结论XRCC1基因rs25487多态性与DLBCL的预后相关。 |
| 关键词: 非霍奇金淋巴瘤 XRCC1 基因 多态性 预后 |
| DOI： |
| 分类号: |
| 基金项目: |
|
| Association between DNA X-ray repair cross complementary protein 1 （XRCC1） polymorphisms and clinical outcome of patients with diffuse large B-cell lymphoma |
|
GAO Yu, WEI Nan, LI Mengjie, JIANG Hao
|
|
Zhejiang Hospital
|
| Abstract: |
| Objective To investigate the association of DNA X-ray repair cross complementary protein 1 (XRCC1) polymorphisms with the clinical outcome of patients with non-Hodgkin's lymphoma (NHL). Methods Sixty five patients with diffuse large B-cell lymphoma (DLBCL)(mean age of 59.7±8.0 years) were enrolled in the study, among whom 31 (47.7%) died from NHL during follow-up. Three single nucleotide polymorphisms (SNPs) in XRCC1 gene of patients were genotyped. Logistic regression analyses were used to compute odds ratios (ORs) and 95% confidence intervals (CIs). Results Among three SNPs,
frequency of A allele of rs25487 was significantly higher in death group than that in survival group(40.3% vs. 22.1%, P＜0.05). The death rates of patients with AA, GA, and GG genotype were 75.0%(6/8), 54.2% (13/24) and 36.4% (12/33), respectively. A allele of rs25487 increased the risk of death in additive model with odds ratio(OR) of 2.208(95%CI:1.039~4.694, P＜0.05). After adjusting for age, sex, smoking, B symptoms and treatment, the significance still remained with OR =2.382 (95%CI:1.057~5.367, P＜0.05). Conclusion rs25487 of XRCC1 gene may be correlated with outcome of DLBCL patients. |
| Key words: Non-Hodgkin's lymphoma XRCC1 gene Polymorphism Prognosis |
